Heartland Bank & Trust Co Takes $596,000 Position in Pfizer Inc. (NYSE:PFE)

Heartland Bank & Trust Co purchased a new position in Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,291 shares of the biopharmaceutical company’s stock, valued at approximately $596,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in PFE. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the 2nd quarter worth $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter valued at $31,000. Creekmur Asset Management LLC bought a new stake in shares of Pfizer during the 4th quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC grew its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.5 %

NYSE:PFE opened at $28.94 on Tuesday. The firm has a market capitalization of $163.96 billion, a P/E ratio of -482.25, a P/E/G ratio of 1.27 and a beta of 0.68. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The company has a fifty day moving average of $29.29 and a 200 day moving average of $28.30. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $34.11.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on PFE shares. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Barclays boosted their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.